Proposals for the measurement of anti‐β2‐glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies

Reber, Guido; Tincani, Anǵela; Sanmarco, Marielle; Moerloose, Philippe de; Boffa, Marie-Claire

doi:10.1111/j.1538-7836.2004.00910.x

Cited by 138 publications

(98 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 In 2004, consensus guidelines and proposals for measurement of aCL and ab2GPI provided advice on sample type, calculation of cut-off values and interpretation of results. 5,6 Recently, a detailed protocol for the performance of aCL enzyme-linked immunosorbent assays (ELISA) 7 and an international consensus guideline on aCL and ab2GPI were published. 8 …”

Section: Introductionmentioning

confidence: 99%

Standardization of antiphospholipid antibody assays. Where do we stand?

Devreese

2012

Lupus

View full text Add to dashboard Cite

The laboratory criteria (lupus anticoagulants (LA), and/or anti-cardiolipin (aCL) antibodies and/or anti-b2-glycoprotein I antibodies (ab2GPI)) that define patients with antiphospholipid syndrome (APS) were set in the Sapporo and Sydney criteria published in 1999 and 2006, respectively, and led to a substantial improvement in the recognition of APS. In addition, guidelines for LA detection were published by the Scientific Standardisation Subcommittee (SSC) of the International Society of Thrombosis and Haemostasis (ISTH) in 2009. However, a number of questions on this respect remain unresolved. Recommendations for the aCL and ab2GPI assays intended to ameliorate the performance of these solid-phase assays. Despite efforts over the years, standardization has not been reached. This review will focus on methodological issues of the three antiphospholipid antibody (aPL) subtypes that are the subject of debate. The use of an international standard for aPL detection might help solve many of the problems caused by a lack of standardization of these assays. Lupus (2012) 21, 718-721.

show abstract

Section: Introductionmentioning

confidence: 99%

Standardization of antiphospholipid antibody assays. Where do we stand?

Devreese

2012

Lupus

View full text Add to dashboard Cite

show abstract

“…APS wants to be pregnant again, pre-conceptional treatment deserves consideration 42 . Some women with APS may need life-long warfarin treatment.…”

Section: Antiphospholipid Syndrome In Pregnancy 169mentioning

confidence: 99%

Antiphospholipid Syndrome in Pregnancy

Haram¹,

Jacobsen²,

Sandset³

2012

Antiphospholipid Syndrome

View full text Add to dashboard Cite

“…It is recommended for each laboratory to establish in-house cut-off values obtained on a population of healthy volunteers with local reagent/instruments combination. 5,6,8,9 The aim of this study was to evaluate the upper limit reference ranges (99 th percentile) used for aCL and a-b2GPI in northwest Italy and to assess the analytical performances of these assays by using normal reference ranges obtained from our own cohort of subjects with and without APS.…”

Section: Introductionmentioning

confidence: 99%

“…These new assays have good analytical performances, excellent intra-assay variation (<10% CV) and may thus reduce the variability between laboratories -a major problem with ELISA kits. [3][4][5][6][7][8][9] However, even with these new platforms, the cut-off values for aCL and a-b2GPI must be carefully chosen, since the diagnostic performance strongly depends on the Correspondence to: B Montaruli, Laboratorio Analisi, AO Ordine Mauriziano, Largo Turati 62, 10128 Turin, Italy Email: bmontaruli@mauriziano.it upper limit reference ranges. It is recommended for each laboratory to establish in-house cut-off values obtained on a population of healthy volunteers with local reagent/instruments combination.…”

Section: Introductionmentioning

confidence: 99%

“…reporting and interpretation of the results). [3][4][5][6][7][8][9] Most commonly, aCL and a-b2GPI are measured by ELISA, although new technologies and automated platforms such as chemiluminiscent (CliA) and fluorescence enzyme (FEIA) immunoassays, have recently been marketed. These new assays have good analytical performances, excellent intra-assay variation (<10% CV) and may thus reduce the variability between laboratories -a major problem with ELISA kits.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-cardiolipin and anti-β2-glycoprotein I antibodies: normal reference ranges in northwestern Italy

Montaruli¹,

Luna²,

Mengozzi

et al. 2012

Lupus

View full text Add to dashboard Cite

Laboratory tests for anticardiolipin antibodies (aCL) and anti-b2glycoprotein I antibodies (a-b2GPI) face problems common to many autoantibody assays: the lack of a reference standard and the need for each laboratory to assess assay-specific cut-off values. The aims of the study were to evaluate the reference range upper limits (99 th percentile) used for aCL and a-b2GPI in the northwest of Italy and to investigate the analytical performances of these assays with the newly obtained reference ranges. We assayed aCL and a-b2GPI in 104 serum samples from patients without a history of thrombosis, pregnancy morbidity, tumours, infections and/or autoimmune diseases (30 males and 74 non-pregnant females). We tested all the commercial assays available in our regions (i.e. Orgentec Diagnostika, Aesku Diagnostics and Inova Diagnostics ELISA; CliA Zenit-RA and EliA Phadia Laboratory Systems). A further 30 serum samples, including 10 from healthy subjects, 10 from antiphospholipid syndrome (APS) patients and 10 from septic patients were assessed to investigate the analytical performance of the obtained cut-off limits. Reference range upper limits obtained with the commercial kits differ among assays and from the values reported by the manufacturer. Moreover, normal reference ranges calculated for IgG and IgM aCL differed from the arbitrary selected laboratory classification values suggested in the guidelines of 40 GPL and MPL. Lupus (2012) 21, 799-801.

show abstract

Proposals for the measurement of anti‐β2‐glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies

Cited by 138 publications

References 13 publications

Standardization of antiphospholipid antibody assays. Where do we stand?

Standardization of antiphospholipid antibody assays. Where do we stand?

Antiphospholipid Syndrome in Pregnancy

Anti-cardiolipin and anti-β2-glycoprotein I antibodies: normal reference ranges in northwestern Italy

Contact Info

Product

Resources

About